SCHEMBL2267923

SCHEMBL2267923

Cc1c(Cl)cccc1C1(O)CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.51
HDAC4 P56524 2/20 0.47
DRD2 P14416 4/20 0.46
OPRM1 P35372 3/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
OPRL1 P41146 2/20 0.38
HTR2C P28335 2/20 0.37
HTR2B P41595 2/20 0.37
ALDH1A1 P00352 1/20 0.36
RXFP1 Q9HBX9 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
DRD3 P35462 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9442653 0.83 HDAC4 (0.56) HDAC4OPRM1OPRK1ALDH1A1GRIN1
SCHEMBL2267707 0.83 SIGMAR1 (0.54) SIGMAR1DRD2OPRM1OPRD1OPRK1
SCHEMBL1513548 0.83 SIGMAR1 (0.50) SIGMAR1DRD2OPRM1OPRD1OPRK1
SCHEMBL652087 0.82 SIGMAR1 (0.57) SIGMAR1HDAC4DRD2OPRM1OPRD1
SCHEMBL2270695 0.80 SIGMAR1 (0.47) SIGMAR1HDAC4DRD2OPRM1OPRD1
SCHEMBL2276508 0.80 SIGMAR1 (0.51) SIGMAR1HDAC4DRD2OPRM1OPRD1
SCHEMBL1513275 0.78 DRD2 (0.55) SIGMAR1DRD2OPRM1OPRD1OPRK1
SCHEMBL3266597 0.77 SIGMAR1 (0.51) SIGMAR1DRD2OPRM1OPRD1OPRK1
SCHEMBL2271814 0.76 SIGMAR1 (0.48) SIGMAR1HDAC4DRD2OPRM1HTR2C
SCHEMBL16638978 0.76 SIGMAR1 (0.44) SIGMAR1DRD2OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 SIGMAR1 3731/4885HDAC4 218/4885DRD2 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.